Combinational Therapy to Overcome High Mortality Rate in HR+, HER2- Breast Cancer

Combinational Therapy to Overcome High Mortality Rate in HR+, HER2- Breast Cancer

Release Date: 19-Nov-2020



There was 25% reduction in the risk of developing recurrence of invasive disease when CDK4/6 inhibitor, abemaciclib was introduced in the patients in combination with some standard endocrine therapy suffering from hormone receptor-positive, HER2-negative, early-stage breast cancer. Although there are number of cancer therapies available for the breast cancer such as chemotherapy or radiation therapy or endocrine therapy, there is high risk of histologic grade 3 disease, and large tumor size, and ultimately disease recurrence. Therefore, in the current therapeutics world, there is an urgent need of a novel and unique therapeutic approach for breast cancer treatment.

 

The drug that got invested in the respective clinical research study i.e. Abemaciclib plus endocrine therapy is estimated to be playing safe role in delivering promising applications in the metastatic setting in this breast cancer subtype. The open label phase 3 clinical research study included patients suffering from hormone receptor-positive, HER2-negative invasive breast cancer. The enrolled patients were given adjuvant endocrine therapy either alone or in combination with the CDK4/6 inhibitor, abemaciclib. Some of the primary aims of the clinical research study was to study about invasive disease-free survival (IDFS), distant relapse-free survival (DRFS), overall survival (OS). Among all the drugs that have been tested for the same, the drug abemaciclib is the first drug to show significant improvement in IDFS when combined with endocrine therapy. As per the researchers involved in the respective study, the future of the clinical trial will include more potential outcomes, leading to a phase where breast cancer mortality rate will be negligible.

 

for the future it will be important to understand if we can potentially spare chemotherapy in this group of patients treated with a CDK4/6 inhibitor. This would need to be investigated in a [randomized] clinical trial.

Need custom market research solution? We can help you with that too.